How should I manage the worsening renal function in an 88-year-old woman with chronic kidney disease (eGFR ~32 mL/min/1.73 m²), hypertension, congestive heart failure, vascular dementia with behavioral disturbance, poor oral intake, and difficulty obtaining IV access, who is taking low-dose aspirin, omeprazole, olmesartan (angiotensin‑II receptor blocker), sodium bicarbonate (Hiprex), and lorazepam (Ativan) PRN?

Managing Declining Renal Function in an 88-Year-Old with CKD Stage 3b

Immediate Priority: Address Volume Status and Medication Review

Your first action should be to optimize her volume status through non-IV routes and immediately review olmesartan for potential temporary discontinuation, as her poor oral intake and declining renal function place her at high risk for acute kidney injury from RAAS blockade during volume depletion. 1

Step 1: Assess and Manage Volume Depletion

• Encourage small, frequent oral fluid intake (30-50 mL every 30 minutes while awake) to achieve gradual rehydration without triggering behavioral resistance 1
• Consider subcutaneous fluid administration (hypodermoclysis) if oral intake remains inadequate—this can deliver 500-1000 mL over several hours without requiring IV access and is well-tolerated in elderly patients with dementia 1
• Temporarily hold olmesartan during this acute period of poor oral intake, as RAAS blockers should be discontinued during intercurrent illness that increases AKI risk in patients with eGFR <60 mL/min/1.73 m² 1

Step 2: Medication Optimization

Continue aspirin and omeprazole without dose adjustment, as neither requires modification at this level of renal function 1

Regarding olmesartan (ARB):

• Resume olmesartan only after oral intake improves and volume status stabilizes 1
• Once restarted, continue the ARB even as eGFR declines below 30 mL/min/1.73 m², as RAAS inhibitors remain nephroprotective and cardioprotective at this stage 1
• Check serum creatinine and potassium within 1 week of restarting to ensure creatinine does not rise >30% and potassium remains <5.5 mEq/L 1
• Accept a creatinine rise up to 30% after restarting olmesartan—this reflects beneficial hemodynamic changes, not harm 1

Minimize Ativan (lorazepam):

• Reduce lorazepam dose by 50% at eGFR 32 mL/min/1.73 m², as benzodiazepines accumulate in renal impairment and worsen confusion 1
• Consider non-pharmacologic behavioral interventions first (music, redirection, consistent caregivers) to minimize sedative needs 1

Step 3: Address Underlying Causes of Renal Decline

Rule out reversible factors:

• Measure urine sodium and fractional excretion of sodium to distinguish prerenal azotemia (volume depletion) from intrinsic kidney disease 1
• Review for nephrotoxic exposures: NSAIDs are absolutely contraindicated at eGFR 32 mL/min/1.73 m² and should never be used 1, 2
• Check urinalysis for active sediment, proteinuria, or infection that might indicate acute interstitial nephritis or glomerulonephritis 1

Step 4: Optimize Blood Pressure Control After Volume Repletion

Target systolic BP 130-140 mmHg (not <120 mmHg) in this 88-year-old with CKD stage 3b, as intensive BP lowering does not provide additional benefit and increases fall risk 1

Once volume status is restored:

• Restart olmesartan at the same dose if BP remains >130/80 mmHg 1
• Add a dihydropyridine calcium channel blocker (e.g., amlodipine 5 mg daily) if BP remains uncontrolled on olmesartan alone, as CCBs require no renal dose adjustment and are effective at all levels of kidney function 1, 3
• Never combine olmesartan with an ACE inhibitor—dual RAAS blockade dramatically increases hyperkalemia and AKI risk without added benefit 1

Step 5: Monitor Potassium Closely

Check serum potassium weekly for the first month after restarting olmesartan, as 37-40% of patients with stage 3 CKD develop hyperkalemia >5.0 mEq/L within 2 months of initiating RAAS blockade 4

If hyperkalemia develops (K >5.5 mEq/L):

• Reduce dietary potassium to <2 g/day and avoid salt substitutes 1
• Add a loop diuretic (furosemide 20-40 mg daily) if residual urine output exists, as thiazides are ineffective at eGFR <30 mL/min/1.73 m² 5
• Continue olmesartan if possible using potassium binders (e.g., patiromer) rather than stopping the ARB, as the cardiovascular and renal benefits outweigh risks 1

Step 6: Consider Cardio-Renal Protective Agents

Initiate an SGLT2 inhibitor (e.g., dapagliflozin 10 mg daily) if she has diabetes, heart failure, or urine albumin-to-creatinine ratio ≥200 mg/g, as SGLT2 inhibitors reduce progression to kidney failure and cardiovascular death even at eGFR 20-45 mL/min/1.73 m² 1

• SGLT2 inhibitors can be started at eGFR ≥20 mL/min/1.73 m² and continued even if eGFR falls below 20 1
• Withhold SGLT2 inhibitors temporarily during prolonged fasting or acute illness to reduce ketosis risk 1

Step 7: Nutritional Support

Consult dietitian for renal-appropriate nutrition to address poor oral intake:

• Provide small, frequent, high-calorie meals (6 small meals daily) to improve intake without overwhelming the patient 1
• Limit dietary sodium to <2 g/day to support BP control and reduce volume retention 5
• Ensure adequate protein (0.8 g/kg/day) unless uremia develops, at which point protein restriction to 0.6 g/kg/day may reduce uremic symptoms 1

Step 8: Plan for Renal Replacement Therapy

Refer to nephrology urgently for dialysis planning if eGFR continues to decline toward 15 mL/min/1.73 m² or if uremic symptoms develop (nausea, pruritus, altered mental status, pericarditis) 5

• Peritoneal dialysis may be preferable to hemodialysis in this patient with difficult IV access and behavioral disturbance 5
• Do not wait until eGFR <10 mL/min/1.73 m² to initiate dialysis planning—access creation requires months 5

Critical Pitfalls to Avoid

• Do not continue olmesartan during acute illness or poor oral intake—this is the most common preventable cause of AKI in CKD patients on RAAS blockers 1
• Do not discontinue olmesartan permanently just because creatinine rose modestly after restarting—rises up to 30% are expected and beneficial 1
• Do not use NSAIDs for any indication at this level of renal function—they will precipitate acute renal failure 1, 2
• Do not assume normal eGFR values exclude CKD—her eGFR of 32 mL/min/1.73 m² definitively indicates stage 3b CKD requiring intervention 6
• Do not delay nephrology referral—patients with eGFR <30 mL/min/1.73 m² require specialist co-management 1